Immune Cells and Secretory Pathways Leading to Human Systemic Autoimmunity

导致人类系统性自身免疫的免疫细胞和分泌途径

• 批准号: 10402544
• 负责人: Maria Virginia Pascual
• 金额: $ 155万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-06-16 至 2024-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10402544
• 关键词: Address; Adult; Area; Autoimmune Diseases; Autoimmunity; B-Lymphocytes; Beds; Bioinformatics; Biological Assay; Biological Markers; Biology; Blood; CD4 Positive T Lymphocytes; CXCR3 gene; Cancer Biology; Cell Compartmentation; Cell physiology; Cells; Child; Child Health; Childhood; Classification; Clinical; Clinical Trials; Clinical Trials Design; Collaborations; Communicable Diseases; Complement; DNA; Data; Dendritic cell activation; Development; Disease; Fibroblasts; Generations; Goals; Heterogeneity; Human; Hypersensitivity; Immune; Immune System Diseases; Immune system; Immunology; In Vitro; Inflammation; Infrastructure; Institutes; International; Knowledge; Lesion; Link; Longitudinal Studies; Lupus Nephritis; Malignant Neoplasms; Medicine; Metabolic; Molecular; Molecular Biology; Monitor; Myelogenous; Myeloid Cells; Neoplasm Metastasis; Nephritis; New York; Pathogenesis; Pathogenicity; Pathologic; Pathway interactions; Patients; Peripheral Blood Mononuclear Cell; Pharmaceutical Preparations; Physiological; Plasma; Population; Recording of previous events; Research; Research Personnel; Resources; Role; Series; Software Engineering; Systemic Lupus Erythematosus; Systemic disease; T-Lymphocyte; T-Lymphocyte Subsets; Technology; Tissues; Translational Research; Work; autoinflammatory; base; cellular targeting; chronic inflammatory disease; cohort; disease heterogeneity; exosome; experience; extracellular; extracellular vesicles; high throughput technology; immunoregulation; insight; intercellular communication; interstitial; multidisciplinary; nanoparticle; new therapeutic target; novel; particle; patient oriented; patient stratification; personalized approach; personalized care; personalized medicine; programs; relapse prediction; response; stem; systemic autoimmune disease; systemic autoimmunity; technological innovation; tool; trafficking; treatment response; tumor; tumor microenvironment; uptake

The Autoimmunity Center of Excellence based at Weill Cornell Medicine (WCM) in New York, NY aims at 1) advancing the knowledge of pathways and mechanisms that contribute to the development and amplification of Human Systemic Autoimmune Diseases (SADs); 2) developing tools and identifying biomarkers to monitor these dysfunctional pathways. Ultimately, we aim to be able to stratify patients towards personalized approaches to treatment. The Center will employ ex vivo and in vitro high throughput technologies and immune profiling to gain insight into the contribution to disease of two major and complementary compartments contributing to systemic disease: Immune Cells and Extra-Cellular Nanoparticles. The appropriate infrastructure is in place to support patient- based studies. In particular, we emphasize the following key conceptual and technological innovations adding to our strengths, that include an established pediatric SLE cohort followed by experienced clinicians with an exceptional record of participation in translational research While the initial focus will be the study of children with Systemic Lupus Erythematosus (SLE), extrapolation of the Center findings to adult SLE as well as other SAD scenarios will be pursued, particularly in the context of the ACE Collaborative efforts. The Drukier Institute for Children’s Health Research at Weill Cornell Medicine has gathered a multidisciplinary team of pediatric basic and patient-oriented investigators with expertise in immunology, autoimmunity, cancer biology, molecular biology, bioinformatics and software engineers, who work together with clinical experts in autoimmunity, cancer, allergy and infectious diseases—from bed-to-bench and bench-to-bed—to understand and treat these diseases. The Institute has also established strong local, national and international collaborations. Dr. Pascual’s team has a long history of productive research in the fields of human autoinflammatory and autoimmune diseases. Dr. Lyden’s group has pioneered the study of exosomes and exomeres, and how these particles horizontally transfer their cargo to recipient cells, thereby acting as vehicles of intercellular communication in both physiological and pathological conditions. The proposed Center is a natural result of the very complementary expertise of these groups and is well-poised to work collaboratively to advance clinical and basic discoveries in the field of human autoimmunity. .

位于纽约州纽约的威尔康奈尔医学中心（WCM）的卓越自身免疫中心的目标是：